AR125118A1 - Actividad antiviral de inhibidores de vps34 - Google Patents

Actividad antiviral de inhibidores de vps34

Info

Publication number
AR125118A1
AR125118A1 ARP210103254A ARP210103254A AR125118A1 AR 125118 A1 AR125118 A1 AR 125118A1 AR P210103254 A ARP210103254 A AR P210103254A AR P210103254 A ARP210103254 A AR P210103254A AR 125118 A1 AR125118 A1 AR 125118A1
Authority
AR
Argentina
Prior art keywords
group
heteroaryl
aryl
c3alkyl
patients
Prior art date
Application number
ARP210103254A
Other languages
English (en)
Inventor
Daniel L Flynn
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of AR125118A1 publication Critical patent/AR125118A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos de tratamiento de infecciones virales, tales como infecciones por coronavirus, en pacientes que lo necesitan, que comprenden administrar a dichos pacientes un inhibidor de VPS34. Reivindicación 1: Un método para paliar o tratar una infección viral en un paciente que lo necesite, caracterizado porque comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable, estereoisómero, o tautómero del mismo, donde: R¹ se selecciona entre el grupo que consiste en arilo y heteroarilo, donde dicho arilo y dicho heteroarilo son monocíclicos o bicíclicos y cada arilo y heteroarilo está opcionalmente sustituido con una o más instancias independientes de un sustituyente seleccionado entre el grupo que consiste en R⁵, R⁶, R⁷ y R⁸; cada R², R³, R⁴ se selecciona en forma independiente entre el grupo que consiste en H, C₁-C₃haloalquilo, y C₁-C₃alquilo; cada R⁵, R⁶, R⁷, y R⁸ se selecciona en forma independiente entre el grupo que consiste en halógeno, C₁-C₆alquilo, C₁-C₆alcoxi, C₁-C₆haloalquilo, amino, -NHSO₂R⁹, hidroxi, fenilo, y un heteroarilo monocíclico; y R⁹ se selecciona entre C₁-C₃haloalquilo y C₁-C₃alquilo.
ARP210103254A 2020-11-25 2021-11-25 Actividad antiviral de inhibidores de vps34 AR125118A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063118512P 2020-11-25 2020-11-25

Publications (1)

Publication Number Publication Date
AR125118A1 true AR125118A1 (es) 2023-06-14

Family

ID=81206898

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103254A AR125118A1 (es) 2020-11-25 2021-11-25 Actividad antiviral de inhibidores de vps34

Country Status (8)

Country Link
US (1) US20220184092A1 (es)
EP (1) EP4251167A1 (es)
JP (1) JP2023550640A (es)
CN (1) CN117136062A (es)
AR (1) AR125118A1 (es)
CA (1) CA3200003A1 (es)
TW (1) TW202237131A (es)
WO (1) WO2022115549A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023009531A2 (pt) 2020-11-18 2023-10-03 Deciphera Pharmaceuticals Llc Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015045A1 (en) * 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
US20230293521A1 (en) * 2020-07-14 2023-09-21 Georgia State University Research Foundation, Inc. Methods for screening novel coronavirus antivirals and methods of using antivirals for the treatment of coronavirus infections

Also Published As

Publication number Publication date
WO2022115549A1 (en) 2022-06-02
CA3200003A1 (en) 2022-06-02
TW202237131A (zh) 2022-10-01
EP4251167A1 (en) 2023-10-04
US20220184092A1 (en) 2022-06-16
JP2023550640A (ja) 2023-12-04
CN117136062A (zh) 2023-11-28

Similar Documents

Publication Publication Date Title
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
AR116604A1 (es) Inhibidores de kras g12c
PE20221339A1 (es) Inhibidores de parp1
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
BR112022000064A2 (pt) Inibidores de hpk1 e usos dos mesmos
CL2020000860A1 (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR125118A1 (es) Actividad antiviral de inhibidores de vps34
AR119614A1 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
ECSP23095674A (es) Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
PE20230180A1 (es) Uso de bi853520 en tratamiento contra el cancer
AR114082A1 (es) INHIBIDORES DE LA PI4KIIIb
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
AR125122A1 (es) Actividad antiviral de inhibidores de vps34
AR125117A1 (es) Actividad antiviral de inhibidores de vps34
AR125120A1 (es) Actividad antiviral de inhibidores de vps34
PE20212333A1 (es) Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
CO2023013321A2 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
AR095595A1 (es) Métodos para tratar las infecciones de gonorrea usando antibióticos de quinolona
EA202190748A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой